Peptonic Medical AB (publ) announced that the European Patent Office ("EPO") has granted a patent for the relief of provoked vulvodynia (previously referred to as vestibulitis), effective until April 2041. VagiVital Intimate Calming Gel, the company's proprietary product designed to alleviate the discomfort associated with vulvodynia, will be launched later this year. The product will also be introduced to existing and new international partners for broad distribution.

VagiVital Intimate Calming Gel provides immediate soothing and moisturizing effects for vulvodynia and relieves symptoms such as dryness, irritation, and itching. The product is based on the company's clinically proven gel formulation and is intended for use on the external genital area. Vulvodynia is a condition characterized by pain around the vaginal opening.

The burden of the condition in a woman's life can be devastating, affecting sexual relationships daily activities, overall well-being, and quality of life. The prevalence of vestibulitis varies between studies but indicates that it affects one to two out of ten women aged 18 to 29. VagiVital Intimate Calming Gel is a valuable addition to Peptonic's existing portfolio of clinically proven self-care products for intimate medical conditions.